Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

LabCorp EVP Mark S. Schroeder sells $1.41m in company stock

Published 03/04/2024, 13:40
LH
-

In a recent transaction on April 1st, Mark S. Schroeder, the Executive Vice President, President of Diagnostics, and Chief Operating Officer of Laboratory Corp of America Holdings (NYSE:LH), sold 6,477 shares of company stock. The shares were sold at a price of $217.29 each, resulting in a total value of approximately $1.41 million.

The sale was executed pursuant to a pre-arranged trading plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Such plans allow insiders to sell a predetermined number of shares at a predetermined time, providing a defense against claims of trading on inside information, as long as the plan was established when the insider was not in possession of material non-public information.

This transaction has changed Schroeder's stake in the company, leaving him with 5,036.1426 shares of Laboratory Corp of America Holdings following the sale. It's worth noting that insider sales can vary in motivation and may not necessarily indicate a negative outlook on the company's future performance.

Investors and market watchers often pay close attention to insider transactions as they can provide insights into how the company's top executives view the stock's valuation and future prospects. Laboratory Corp of America Holdings, with its ticker symbol LH, is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.

The details of the transaction were made public through a Form 4 filing with the Securities and Exchange Commission on April 3rd, two days after the shares were sold.

InvestingPro Insights

As investors digest the recent insider transaction at Laboratory Corp of America Holdings (NYSE:LH), it's crucial to consider the broader financial landscape of the company. With a market capitalization of $17.82 billion and a P/E ratio standing at 43.99, the company's valuation reflects a significant earnings multiple. However, when adjusted for the last twelve months as of Q4 2023, the P/E ratio becomes more grounded at 26.35. This suggests a more reasonable valuation in the context of the company's earnings.

One of the noteworthy InvestingPro Tips for Laboratory Corp of America Holdings is that management has been actively engaging in share buybacks, which often signals confidence in the company's future and can indicate potential value for shareholders. Additionally, the company is recognized for its high shareholder yield, which encompasses both dividends and buybacks, providing a more holistic view of shareholder returns.

From a performance standpoint, the company's revenue in the last twelve months as of Q4 2023 totaled $12.16 billion, with a modest growth rate of 2.51%. The gross profit margin during the same period was healthy at 27.67%, indicating a solid ability to control costs relative to revenue.

For those looking to delve deeper into the financial health and future prospects of Laboratory Corp of America Holdings, InvestingPro offers a range of additional tips. There are currently 6 more InvestingPro Tips available, which could provide valuable insights into the company's profitability and industry standing. Interested readers can find these tips at Investing.com/pro/LH and can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.